热门资讯> 正文

Corcept的卵巢癌治疗正在接受FDA审查

2025-09-10 20:51

Corcept Therapeutics (NASDAQ:CORT) said that the U.S. FDA will review its marketing application for relacorilant, its oral therapy, for the treatment of platinum-resistant ovarian cancer.
The agency has assigned a target action date of July 11, 2026.
Corcept’s application is based on positive data from its pivotal trials.

More on Corcept Therapeutics

Corcept's Q2 Demand Grows 60%, Penetrating Large Type 2 Diabetes Market Early
Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call Transcript
Beyond Cushing's: The Undervalued Potential Of Corcept's Cortisol Modulators
Corcept anticipates relacorilant approval and projects $3B–$5B annual hypercortisolism revenue by 2028 as pharmacy capacity expands
Corcept Therapeutics GAAP EPS of $0.90 beats by $0.71, revenue of $194.4M misses by $4.99M

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。